Yoshikane Y, Okuma Y, Miyamoto T, et al. - A prospective cohort study was conducted to evaluate whether the serum level of tenascin-C could be used as a novel biomarker to predict the risk of resistance to initial treatment for high-risk patients. Researchers enrolled a total of 380 Kawasaki disease patients and provided serum samples for tenascin-C measurement before commencing their initial treatment. They compared patient clinical and laboratory data, including the serum tenascin-C level, between initial treatment responders and non-responders. The results indicate that serum tenascin-C could be a biomarker for predicting the risk of high-risk patients being non-responsive to steroid combination therapy.